MedWatch

Analysts: CNS experience a plus for new Lundbeck EVP

Experience with diseases in the central nervous system is an advantage for Lundbeck's new head of Research and Development. Nevertheless, he is an unknown quantity in the industry.

Foto: Ritzau Scanpix/Torkil Adsersen

It did not take long before Danish drug group Lundbeck appointed the successor of long-serving executive vice president for Research and Development, Anders Gersel Pedersen.

The new EVP, Johan Luthman, is a rather unknown quantity - perhaps because he joins Lundbeck from a position as senior vice president in Eisai and thus have not been as visible as the executive management. The stock market's reception of the new EVP was also relatively modest - Tuesday morning, the share price increased by just one percent.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier